MA33503B1 - L-asparaginase pegylée - Google Patents
L-asparaginase pegyléeInfo
- Publication number
- MA33503B1 MA33503B1 MA34598A MA34598A MA33503B1 MA 33503 B1 MA33503 B1 MA 33503B1 MA 34598 A MA34598 A MA 34598A MA 34598 A MA34598 A MA 34598A MA 33503 B1 MA33503 B1 MA 33503B1
- Authority
- MA
- Morocco
- Prior art keywords
- conjugate
- relates
- asparaginase
- protein
- polyethylene glycol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
- C12N9/82—Asparaginase (3.5.1.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
- C12Y305/01001—Asparaginase (3.5.1.1)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
L'invention porte sur un conjugué d'une protéine ayant une activité l-asparagine aminohydrolase substantielle et du polyéthylène glycol. En particulier, le polyéthylène glycol a une masse moléculaire inférieure ou égale à environ 5 000 da, et la protéine est une l-asparaginase d'erwinia. Le conjugué de l'invention a présenté des propriétés supérieures telles que l'entretien d'un taux élevé d'activité in vitro et une augmentation inattendue de demi-vie in vivo. L'invention porte également sur des procédés de fabrication du conjugué et sur l'utilisation du conjugué en thérapie. En particulier, l'invention porte sur un procédé d'utilisation du conjugué dans le traitement du cancer, en particulier d'une leucémie lymphoblastique aigüe (all). Plus spécifiquement, l'invention porte sur un procédé pour l'utilisation du conjugué en tant que thérapie de seconde ligne pour des patients qui ont développé une hypersensibilité ou ont eu une rechute de maladie après traitement par d'autres préparations de l-asparaginase.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22332009P | 2009-07-06 | 2009-07-06 | |
| PCT/EP2010/054156 WO2011003633A1 (fr) | 2009-07-06 | 2010-03-30 | L-asparaginase pegylée |
| PCT/EP2010/059599 WO2011003886A1 (fr) | 2009-07-06 | 2010-07-06 | L-asparaginase pegylée |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA33503B1 true MA33503B1 (fr) | 2012-08-01 |
Family
ID=42232655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA34598A MA33503B1 (fr) | 2009-07-06 | 2010-07-06 | L-asparaginase pegylée |
Country Status (26)
| Country | Link |
|---|---|
| US (6) | US20120100121A1 (fr) |
| JP (1) | JP6014956B2 (fr) |
| KR (1) | KR101731999B1 (fr) |
| CN (1) | CN102573917B (fr) |
| AU (1) | AU2010270294B2 (fr) |
| BR (1) | BR112012000367A2 (fr) |
| CA (1) | CA2767149C (fr) |
| CO (1) | CO6612174A2 (fr) |
| DK (1) | DK2451486T4 (fr) |
| EA (1) | EA021168B1 (fr) |
| ES (1) | ES2636476T5 (fr) |
| FI (1) | FI2451486T4 (fr) |
| HK (1) | HK1173092A1 (fr) |
| HU (1) | HUE035771T2 (fr) |
| IL (1) | IL217392A (fr) |
| IN (1) | IN2012DN00958A (fr) |
| LT (1) | LT2451486T (fr) |
| MA (1) | MA33503B1 (fr) |
| MX (1) | MX2012000424A (fr) |
| MY (1) | MY180758A (fr) |
| NZ (1) | NZ597912A (fr) |
| PE (2) | PE20161325A1 (fr) |
| PT (1) | PT2451486T (fr) |
| SG (1) | SG176984A1 (fr) |
| UA (1) | UA104634C2 (fr) |
| WO (2) | WO2011003633A1 (fr) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE531779C2 (sv) * | 2007-11-26 | 2009-08-04 | Promimic Ab | Framställning av kalciumfosfatpartiklar i nanostorlek som pulver eller beläggning via bifunktionella prekursorer |
| WO2011003633A1 (fr) * | 2009-07-06 | 2011-01-13 | Alize Pharma Ii | L-asparaginase pegylée |
| WO2015033344A1 (fr) | 2013-09-05 | 2015-03-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Procédés et nécessaires permettant d'inhiber la pathogénicité d'un streptocoque du groupe a (sga) ou d'un streptocoque du groupe g (sgg) |
| WO2015038639A1 (fr) * | 2013-09-10 | 2015-03-19 | Sandia Corporation | Asparaginases thérapeutiques |
| CN104046600B (zh) * | 2013-12-30 | 2019-04-05 | 江苏众红生物工程创药研究院有限公司 | 多臂聚乙二醇修饰剂的新用途及其在修饰门冬酰胺酶中的应用 |
| BR102014000585B1 (pt) | 2014-01-10 | 2021-01-12 | Coppe/Ufrj-Instituto Alberto Luiz Coimbra De Pós-Graduação | l-asparaginase recombinante de zymomonas |
| US9808011B2 (en) | 2014-12-15 | 2017-11-07 | Biovectra Inc. | Pentacyclic triterpene compounds and uses thereof |
| CN105802948B (zh) | 2014-12-29 | 2020-06-09 | 江苏众红生物工程创药研究院有限公司 | 聚乙二醇定点修饰的门冬酰胺酶及其制备方法与应用 |
| WO2017055484A1 (fr) | 2015-09-29 | 2017-04-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Procédés de détermination du statut métabolique des lymphomes |
| CA3054286A1 (fr) | 2016-03-01 | 2017-09-08 | The Board Of Trustees Of The University Of Illinois | Variants et proteines de fusion de l-asparaginase ayant une activite l-glutaminase reduite et une stabilite amelioree |
| KR20230162139A (ko) * | 2016-06-01 | 2023-11-28 | 세르비에 아이피 유케이 리미티드 | 폴리알킬렌 옥시드-아스파라기나제의 제형, 및 그의 제조 및 사용 방법 |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11504418B2 (en) * | 2016-11-04 | 2022-11-22 | Crowpierce Technologies, Llc | Endotoxin free asparaginase |
| SG11201912625QA (en) * | 2017-06-21 | 2020-01-30 | Jazz Pharmaceuticals Ireland Ltd | Modified l-asparaginase |
| US10174302B1 (en) | 2017-06-21 | 2019-01-08 | Xl-Protein Gmbh | Modified L-asparaginase |
| EP3418383A1 (fr) * | 2017-06-21 | 2018-12-26 | XL-protein GmbH | L-asparaginase modifié |
| EP3701036A4 (fr) | 2017-10-27 | 2021-09-01 | Pfenex Inc. | Procédé de production d'une asparaginase d'e. coli |
| SG11202002943PA (en) * | 2017-10-27 | 2020-05-28 | Pfenex Inc | Method for production of recombinant erwinia asparaginase |
| MX2020005567A (es) * | 2017-11-30 | 2020-08-20 | Jazz Pharmaceuticals Ireland Ltd | Metodos de tratamiento con asparaginasa. |
| WO2019204636A1 (fr) * | 2018-04-19 | 2019-10-24 | Kindred Biosciences, Inc. | Polypeptides variants d'asparaginase à usage médical |
| CN113473980A (zh) | 2019-03-01 | 2021-10-01 | 弗拉梅尔爱尔兰有限公司 | 在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物 |
| GB201912020D0 (en) * | 2019-08-21 | 2019-10-02 | Porton Biopharma Ltd | Therapeutic Conjugate |
| AU2020371963A1 (en) * | 2019-10-25 | 2022-05-26 | Jazz Pharmaceuticals Ireland Ltd. | Recombinant L-asparaginase |
| KR102269634B1 (ko) * | 2019-10-31 | 2021-06-25 | 대상 주식회사 | ansB 유전자 불활성화에 의해 아미노산 생산능력이 향상된 균주 |
| CN116916966A (zh) | 2020-12-23 | 2023-10-20 | 爵士制药爱尔兰有限公司 | 纯化电荷屏蔽融合蛋白的方法 |
| WO2022211829A1 (fr) | 2021-03-30 | 2022-10-06 | Jazz Pharmaceuticals Ireland Ltd. | Dosage de l-asparaginase recombinante |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| WO2024008659A1 (fr) | 2022-07-04 | 2024-01-11 | Institut National de la Santé et de la Recherche Médicale | Utilisation d'une l-asparaginase en combinaison avec un inducteur de ferroptose pour le traitement du lymphome à cellules nk/t extranodal |
| WO2024015529A2 (fr) | 2022-07-14 | 2024-01-18 | Jazz Pharmaceuticals Ireland Ltd. | Polythérapies impliquant la l-asparaginase |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| US5286637A (en) | 1989-08-07 | 1994-02-15 | Debiopharm, S.A. | Biologically active drug polymer derivatives and method for preparing same |
| US5766897A (en) | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
| GB9017002D0 (en) * | 1990-08-02 | 1990-09-19 | Health Lab Service Board | Improved method for the purification of erwina l-asparaginase |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| US5681811A (en) | 1993-05-10 | 1997-10-28 | Protein Delivery, Inc. | Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same |
| US5359030A (en) | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
| US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
| US5776746A (en) | 1996-05-01 | 1998-07-07 | Genitope Corporation | Gene amplification methods |
| US6309633B1 (en) | 1999-06-19 | 2001-10-30 | Nobex Corporation | Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same |
| US20020065397A1 (en) | 2000-10-12 | 2002-05-30 | Joseph Roberts | Protecting therapeutic compositions from host-mediated inactivation |
| US6913915B2 (en) * | 2001-08-02 | 2005-07-05 | Phoenix Pharmacologics, Inc. | PEG-modified uricase |
| AU2002332371A1 (en) * | 2001-08-22 | 2003-03-10 | Gosudarstvennoe Uchrezhdenie Nauchno-Issledovatelsky Institut Biomeditsinskoy Khimii Im. Orekhovicha | Recombinant l-asparaginase less thanigreater thanerwinia caratovoraless than/igreater than |
| ES2420581T3 (es) | 2003-03-14 | 2013-08-26 | Biogenerix Gmbh | Polímeros solubles en agua ramificados y sus conjugados |
| WO2007103290A2 (fr) | 2006-03-03 | 2007-09-13 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Substances et méthodes thérapeutiques axées sur l' asparagine synthétase et l'asparaginase |
| US20090167164A1 (en) | 2006-04-21 | 2009-07-02 | Konica Minolta Holdings, Inc. | Gas barrier film, resin base for organic electroluminescent device, organic electroluminescent device using the same, and method for producing gas barrier film |
| WO2008110513A1 (fr) * | 2007-03-09 | 2008-09-18 | Novozymes A/S | Asparaginases |
| WO2011003633A1 (fr) | 2009-07-06 | 2011-01-13 | Alize Pharma Ii | L-asparaginase pegylée |
| US11433136B2 (en) | 2015-12-18 | 2022-09-06 | The General Hospital Corporation | Polyacetal polymers, conjugates, particles and uses thereof |
-
2010
- 2010-03-30 WO PCT/EP2010/054156 patent/WO2011003633A1/fr active Application Filing
- 2010-07-06 DK DK10730170.7T patent/DK2451486T4/da active
- 2010-07-06 JP JP2012518956A patent/JP6014956B2/ja active Active
- 2010-07-06 AU AU2010270294A patent/AU2010270294B2/en active Active
- 2010-07-06 FI FIEP10730170.7T patent/FI2451486T4/fi active
- 2010-07-06 EA EA201270134A patent/EA021168B1/ru not_active IP Right Cessation
- 2010-07-06 UA UAA201201135A patent/UA104634C2/ru unknown
- 2010-07-06 SG SG2011096013A patent/SG176984A1/en unknown
- 2010-07-06 PE PE2016001555A patent/PE20161325A1/es unknown
- 2010-07-06 KR KR1020127003202A patent/KR101731999B1/ko active IP Right Grant
- 2010-07-06 PT PT107301707T patent/PT2451486T/pt unknown
- 2010-07-06 MY MYPI2012000054A patent/MY180758A/en unknown
- 2010-07-06 LT LTEP10730170.7T patent/LT2451486T/lt unknown
- 2010-07-06 NZ NZ597912A patent/NZ597912A/en unknown
- 2010-07-06 HU HUE10730170A patent/HUE035771T2/en unknown
- 2010-07-06 US US13/382,276 patent/US20120100121A1/en not_active Abandoned
- 2010-07-06 WO PCT/EP2010/059599 patent/WO2011003886A1/fr active Application Filing
- 2010-07-06 MX MX2012000424A patent/MX2012000424A/es active IP Right Grant
- 2010-07-06 CA CA2767149A patent/CA2767149C/fr active Active
- 2010-07-06 BR BR112012000367A patent/BR112012000367A2/pt not_active Application Discontinuation
- 2010-07-06 MA MA34598A patent/MA33503B1/fr unknown
- 2010-07-06 CN CN201080030392.6A patent/CN102573917B/zh active Active
- 2010-07-06 PE PE2012000023A patent/PE20120501A1/es not_active Application Discontinuation
- 2010-07-06 ES ES10730170T patent/ES2636476T5/es active Active
-
2012
- 2012-01-05 IL IL217392A patent/IL217392A/en active IP Right Grant
- 2012-02-02 IN IN958DEN2012 patent/IN2012DN00958A/en unknown
- 2012-02-06 CO CO12020409A patent/CO6612174A2/es unknown
-
2013
- 2013-01-11 HK HK13100524.0A patent/HK1173092A1/xx unknown
-
2015
- 2015-08-05 US US14/819,305 patent/US9920311B2/en not_active Ceased
-
2018
- 2018-02-01 US US15/886,216 patent/US20180346900A1/en not_active Abandoned
-
2020
- 2020-03-18 US US16/822,764 patent/USRE49736E1/en active Active
- 2020-05-18 US US16/877,324 patent/US11046946B2/en active Active
-
2021
- 2021-06-03 US US17/338,508 patent/US20210348151A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA33503B1 (fr) | L-asparaginase pegylée | |
| AU2021203382B2 (en) | Therapeutic pooled blood apoptotic cell preparations and uses thereof | |
| US20220241347A1 (en) | Placenta-derived adherent cell exosomes and uses thereof | |
| Winkler et al. | Hematopoietic stem cell mobilizing agents G-CSF, cyclophosphamide or AMD3100 have distinct mechanisms of action on bone marrow HSC niches and bone formation | |
| JP6884155B2 (ja) | 癌治療のための併用免疫療法及びサイトカイン制御療法 | |
| US11957713B2 (en) | Compositions and methods for treating diseases and disorders of the central nervous system | |
| TWI322184B (en) | Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates | |
| JP2012532185A5 (fr) | ||
| Zhang et al. | Gene therapy of ovarian cancer using IL-21-secreting human umbilical cord mesenchymal stem cells in nude mice | |
| KR20170131562A (ko) | 암 약물과의 조합 요법에서의 nk-92 세포 | |
| US9610331B2 (en) | Methods for hematopoietic precursor mobilization | |
| Koga et al. | Efficacy of a cultured conditioned medium of exfoliated deciduous dental pulp stem cells in erectile dysfunction patients | |
| Che et al. | Lymph‐Node‐Targeted Drug Delivery for Effective Immunomodulation to Prolong the Long‐Term Survival After Heart Transplantation | |
| Stansel et al. | NF-κB inhibition suppresses experimental melanoma lung metastasis | |
| JP7412576B2 (ja) | 腎がんの相乗的治療におけるペグインターフェロンおよびプロトオンコジーン産物標的阻害剤の適用 | |
| JP7076103B2 (ja) | 中枢神経腫瘍の処置 | |
| Black et al. | Analysis of Propionibacterium amis‐induced non‐specific immunity to Trypanosoma brucei in mice | |
| Rajkovic | Reactive oxygen species responsive polysulfide nanoparticles for treatment of ischaemic stroke | |
| WO2024103313A1 (fr) | Thérapie anticancéreuse basée sur le ciblage d'irg1 | |
| Mukti et al. | Mesenchymal stem cells enhance vascular endothelial growth factor-A, endothelial nitric oxide synthetase, and HSP70 expression in improving erectile dysfunction in streptozotocin-induced diabetic rats | |
| Itoh et al. | Sulfasalazine, a potent cystine-glutamate transporter inhibitor, enhances osteogenic differentiation of canine adipose-derived stem cells | |
| WO2022056117A1 (fr) | Compositions d'acide nucléique-polypeptide et leurs utilisations | |
| WO2023042209A2 (fr) | Traitement de malignités myéloïdes | |
| CA3155360A1 (fr) | Procedes et compositions pour le traitement de l'endometriose | |
| WO2020056161A1 (fr) | Vaccin à nanoparticules à base d'arn cellulaire à cycle lent permettant de traiter le cancer |